187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

USC Norris opens Keck Medicine of USC–Newport Beach Radiation Oncology and Imaging center

USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has opened Keck Medicine of USC–Newport Beach Radiation Oncology and Imaging, a new radiation oncology and imaging center, at 4590 MacArthur Blvd. in Newport Beach, CA.

April 18, 2025

Vol.51 No.15

Trials & Tribulations

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

David Liu awarded 2025 Breakthrough Prize in Life Sciences

Howard Hughes Medical Institute Investigator David R. Liu was awarded the 2025 Breakthrough Prize in Life Sciences for developing two gene-editing technologies—known as base editing and prime editing—which enable the correction or replacement of virtually any genetic mutation, including those that cause countless human genetic diseases.

April 11, 2025

Vol.51 No.14

Clinical Roundup

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

YOU MAY BE INTERESTED IN

USC Norris opens Keck Medicine of USC–Newport Beach Radiation Oncology and Imaging center

Genetic counseling can improve genetic screening and accelerate clinical trial success

David Liu awarded 2025 Breakthrough Prize in Life Sciences

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Renew today!

Subscriber content

Never miss an issue!

Login